FMP
Xenon Pharmaceuticals Inc.
XENE
NASDAQ
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
35.32 USD
0.14 (0.396%)
XENE Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-181.39M
-145.33M
-98.43M
-69.5M
Net Income
-234.33M
-182.39M
-125.37M
-78.88M
Depreciation & Amortization
0
3.54M
1.62M
906k
Deferred Income Taxes
-8.86M
-292k
-44k
58k
Stock Based Compensation
50.72M
32.37M
20.38M
10.02M
Change in Working Capital
0
5.63M
-676k
-2.65M
Accounts Receivable
0
130k
1.76M
-459k
Inventory
0
0
0
-2.97M
Accounts Payable
0
3.93M
8.06M
2.97M
Other Working Capital
6.33M
1.57M
-10.49M
-2.19M
Other Non-Cash Items
11.09M
-4.19M
5.66M
1.05M
CF from Investing Activities
165M
-117.17M
-296M
-246.77M
Investments in Property, Plant & Equipment
0
-5.62M
-2.89M
-2.05M
Net Acquisitions
0
0
296M
-144.75M
Investment Purchases
0
-793.91M
-551.14M
-389.47M
Sales/Maturities of Investments
0
682.35M
258.03M
144.75M
Other Investing Activites
165M
0
-296M
144.75M
CF from Financing Activities
12.13M
353.52M
278.47M
447.54M
Debt Repayment
0
0
0
0
Common Stock Issued
12.08M
353.49M
277.77M
447.28M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
47k
35k
705k
260k
Free Cash Flow
-181.39M
-150.94M
-101.32M
-71.55M
Operating Cash Flow
-181.39M
-145.33M
-98.43M
-69.5M
Capital Expenditures
0
-5.62M
-2.89M
-2.05M
Cash at Beginning of Period
148.64M
57.24M
175.69M
45.01M
Cash at End of Period
142.71M
148.64M
57.24M
175.69M
Net Change In Cash
-5.93M
91.4M
-118.45M
130.68M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-665.14M
-482.75M
-357.37M
-278.49M
Net Income
-234.33M
-182.39M
-125.37M
-78.88M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-899.47M
-665.14M
-482.75M
-357.37M
Other Distributions
-234.33M
-182.39M
-125.37M
-78.88M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
18.22M
18.85M
16.91M
12.52M
Annual Depreciation
0
3.54M
1.62M
906k
Capital Expenditure
0
-5.62M
-2.89M
-2.05M
Net PPE
18.22M
20.92M
18.18M
13.67M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
